Shanghai HeartCare Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting life and health. In the past six years, HeartCare Medical has pioneered the creation of the first one-stop solution for stroke treatment and prevention in China in the field of neurological intervention. It owns the whole product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention and hemorrhagic stroke treatment to interventional access equipment, and has applied for more than 300 patents, and its sales channels cover all provinces nationalwide other than Hong Kong, Macao and Taiwan.
Based on the existing leading advantages, HeartCare Medical will continue to focus on popularizing new medical techniques, focus on the unmet needs of clinicians and patients in China, and operate a number of new business segments including nerve intervention, Cardiac therapy, pulmonary intervention and computer-aided technology, expecting that in these medical fields with great potential, Continuously introduce innovative interventional instruments that define new surgical methods to reduce the mortality of major diseases and improve the prognosis of patients.